Brief: Clover Biopharmaceuticals Says Gavi Files Arbitration Request Against Clover HK
09/06/2025 02:00
June 9 (Reuters) - Clover Biopharmaceuticals Ltd 2197.HK: GAVI FILES ARBITRATION REQUEST AGAINST CLOVER HK FOR REPAYMENT TO DEFEND AGAINST GAVI CLAIM CONTINUES DEVELOPMENT OF RSV VACCINE CANDIDATE SCB-1019 Further company coverage: 2197.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clover Biopharmaceuticals
See all newsChina's Clover Biopharma H1 revenue drops sharply, flags going-concern doubt
Brief: Clover Biopharmaceuticals Posts FY Loss Of RMB205.1 MLN
Brief: Clover Announces Positive Phase I Clinical Data For Rsv-Hmpv-Piv3 Combination Vaccines And For Rsv Re-Vaccination In Older Adults
Brief: Clover Biopharmaceuticals Posts H1 Revenue Of RMB3.3 Million
Brief: Clover Biopharmaceuticals Says It Terminates Cooperation With Adimmune